NCT03010358 · OUTCOME

Pharmacodynamics Parameters of NFkappaB Activation and Expression of Anti-apoptotic Proteins in Chronic Lymphocytic Leukemia (CLL) Cells

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma · Source last updated 2023-08-08

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 45 months

What was measured

Pharmacokinetic parameters including peak and trough levels will be determined by noncompartmental method(s) using the pharmacokinetic profile of entospletinib and obinutuzumab.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Pharmacokinetic parameters including peak and trough levels will be determined by noncompartmental method(s) using the pharmacokinetic profile of entospletinib and obinutuzumab.
reporting Status: NOT_POSTED
time Frame: Up to 45 months
title: Pharmacodynamics Parameters of NFkappaB Activation and Expression of Anti-apoptotic Proteins in Chronic Lymphocytic Leukemia (CLL) Cells
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice